company background image
SPAG

Spago Nanomedical OM:SPAGO Stock Report

Last Price

kr0.85

Market Cap

kr77.3m

7D

-3.0%

1Y

-86.7%

Updated

04 Oct, 2022

Data

Company Financials +
SPAGO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

SPAGO Stock Overview

Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden.

Spago Nanomedical AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Spago Nanomedical
Historical stock prices
Current Share Pricekr0.85
52 Week Highkr6.97
52 Week Lowkr0.74
Beta2.21
1 Month Change-9.57%
3 Month Change-28.27%
1 Year Change-86.74%
3 Year Change-91.91%
5 Year Change-90.86%
Change since IPO-93.93%

Recent News & Updates

Shareholder Returns

SPAGOSE BiotechsSE Market
7D-3.0%17.0%5.1%
1Y-86.7%-28.8%-24.4%

Return vs Industry: SPAGO underperformed the Swedish Biotechs industry which returned -29.8% over the past year.

Return vs Market: SPAGO underperformed the Swedish Market which returned -26.1% over the past year.

Price Volatility

Is SPAGO's price volatile compared to industry and market?
SPAGO volatility
SPAGO Average Weekly Movement6.3%
Biotechs Industry Average Movement8.5%
Market Average Movement7.0%
10% most volatile stocks in SE Market11.5%
10% least volatile stocks in SE Market4.3%

Stable Share Price: SPAGO is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: SPAGO's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199915Mats Hansenhttps://spagonanomedical.se

Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014.

Spago Nanomedical AB (publ) Fundamentals Summary

How do Spago Nanomedical's earnings and revenue compare to its market cap?
SPAGO fundamental statistics
Market Capkr77.30m
Earnings (TTM)-kr40.84m
Revenue (TTM)kr6.03m

12.8x

P/S Ratio

-1.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SPAGO income statement (TTM)
Revenuekr6.03m
Cost of Revenuekr22.54m
Gross Profit-kr16.51m
Other Expenseskr24.33m
Earnings-kr40.84m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 08, 2022

Earnings per share (EPS)-0.45
Gross Margin-273.89%
Net Profit Margin-677.52%
Debt/Equity Ratio0.0%

How did SPAGO perform over the long term?

See historical performance and comparison